All patients in this cohort received ICIs [either as single agent (PD-1 or CTLA4 inhibitors) or in combination (PD-1 and CTLA4 inhibitors)] and exhibited either primary or acquired resistance to therapy, and all were ICI refractory at the time of death and tumor sampling. The gene discussed is CTLA4; the disease is neoplasm.